Shares of Sai Parenteral's Ltd. listed at a marginal premium on the stock market on Thursday. The scrip opened 2% higher at ...

The HHS Secretary told podcaster Joe Rogan that he hoped to see movement on peptides from the FDA within weeks.

Excipient innovation is part of a broader eco-design strategy that integrates sustainability into every stage of product development. By reducing energy consumption, minimizing waste, and sourcing ...

MYRTLE BEACH, SC, UNITED STATES, April 1, 2026 /EINPresswire.com/ -- Skincare Innovator and Healthcare Professional ...

Inhibitor Therapeutics, Inc. (OTCQB: INTI) ("Inhibitor" or the "Company"), today provided an update on its ongoing pharmacokinetic (PK) clinical program supporting the treatment of surgically eligible ...

Shares of Sai Parenterals were currently trading at Rs 412.05 at 10:05 IST on the BSE, representing a premium of 4.50% as compared with the issue price of Rs 392.

Alto Neuroscience missed the primary endpoint for a study of its ALTO-101 drug for the treatment of cognitive impairment associated with schizophrenia.

Glenmark Pharmaceuticals Inc., USA (Glenmark) today announced that it will manage end-to-end commercialization and distribution for RYALTRIS® (Olopatadine Hydrochloride and Mometasone Furoate) Nasal ...

Growel Formulations announced a strategic investment in Provet Pharma, boosting its presence in the high-growth poultry ...

Orforglipron is the first new molecular entity cleared under the FDA's Commissioner's National Priority Voucher (CNPV) pilot ...

Patients with non-squamous non-small cell cancer may achieve similar outcomes with a subcutaneous formulation of the immunotherapy toripalimab as with IV administration.

With conflict in the Middle East bringing on a global energy market squeeze, one major pharma supplier is raising prices ...